References
- N. Klauber-DeMore, B.A. Schulte, and G.Y. Wang, Targeting MYC for triple-negative breast cancer treatment, Oncoscience 5 (2018), pp. 120–121. doi:https://doi.org/10.18632/oncoscience.414.
- I. Januškevičienė and V. Petrikaitė, Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations, Life Sci. 239 (2019), pp. 117009. doi:https://doi.org/10.1016/j.lfs.2019.117009.
- S. Gholami, C. Chen, S. Gao, E. Lou, S. Fujisawa, J. Carson, J. Nnoli, T. Chou, J. Bromberg, and Y. Fong, Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer, Cancer Gene Ther. 21 (2014), pp. 283–289. doi:https://doi.org/10.1038/cgt.2014.28.
- J.M. Giltnane and J.M. Balko, Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer, Discov. Med. 17 (2014), pp. 275–283.
- B.C. Lechtenberg, P.D. Mace, E.H. Sessions, R. Williamson, R. Stalder, Y. Wallez, G.P. Roth, S.J. Riedl, and E.B. Pasquale, Structure-guided strategy for the development of potent bivalent ERK inhibitors, ACS Med. Chem. Lett. 8 (2017), pp. 726–731. doi:https://doi.org/10.1021/acsmedchemlett.7b00127.
- W. Jiang, X. Wang, C. Zhang, L. Xue, and L. Yang, Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer, Oncol. Lett. 19 (2020), pp. 1842–1848. doi:https://doi.org/10.3892/ol.2020.11274.
- Y. Sun, W.-Z. Liu, T. Liu, X. Feng, N. Yang, and H.-F. Zhou, Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis, J. Recept. Signal Transduct. 35 (2015), pp. 600–604. doi:https://doi.org/10.3109/10799893.2015.1030412.
- F. Liu, X. Yang, M. Geng, and M. Huang, Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy, Acta Pharm. Sin. B 8 (2018), pp. 552–562. doi:https://doi.org/10.1016/j.apsb.2018.01.008.
- S. Pathania and R.K. Rawal, An update on chemical classes targeting ERK1/2 for the management of cancer, Future Med. Chem. 12 (2020), pp. 593–611. doi:https://doi.org/10.4155/fmc-2019-0339.
- Z. Yu, S. Ye, G. Hu, M. Lv, Z. Tu, K. Zhou, and Q. Li, The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles to effective cancer therapy, Future Med. Chem. 7 (2015), pp. 269–289. doi:https://doi.org/10.4155/fmc.14.143.
- J.A. McCubrey, L.S. Steelman, S.L. Abrams, J.T. Lee, F. Chang, F.E. Bertrand, P.M. Navolanic, D.M. Terrian, R.A. Franklin, and A.B. D’Assoro, Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance, Adv. Enzyme Regul. 46 (2006), pp. 249–279. doi:https://doi.org/10.1016/j.advenzreg.2006.01.004.
- S.N. Rao, Tracking binding modes of 1, 2, 4-trisubstituted imidazolinone P38 MAP kinase and ERK-2 inhibitors, J. Mol. Graph. Model. 76 (2017), pp. 161–171. doi:https://doi.org/10.1016/j.jmgm.2017.07.001.
- S.B. Boga, A.-B. Alhassan, A.B. Cooper, R. Doll, N.-Y. Shih, G. Shipps, Y. Deng, H. Zhu, Y. Nan, and R. Sun, Discovery of 3 (S)-thiomethyl pyrrolidine ERK inhibitors for oncology, Bioorg. Med. Chem. Lett. 28 (2018), pp. 2029–2034. doi:https://doi.org/10.1016/j.bmcl.2018.04.063.
- A.A. Aly, E.M. El-Sheref, M.E. Bakheet, M.A. Mourad, A.B. Brown, S. Bräse, M. Nieger, and M.A. Ibrahim, Synthesis of novel 1, 2-bis-quinolinyl-1, 4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies, Bioorg. Chem. 81 (2018), pp. 700–712. doi:https://doi.org/10.1016/j.bioorg.2018.09.017.
- A. Speck-Planche, V.V. Kleandrova, F. Luan, and M.N.D. Cordeiro, Chemoinformatics in anti-cancer chemotherapy: Multi-target QSAR model for the in silico discovery of anti-breast cancer agents, Eur. J. Pharm. Sci. 47 (2012), pp. 273–279. doi:https://doi.org/10.1016/j.ejps.2012.04.012.
- A. Speck-Planche and M.N.D. Cordeiro, Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins, Mol. Divers. 21 (2017), pp. 511–523. doi:https://doi.org/10.1007/s11030-017-9731-1.
- T. Wang, Y. Wang, X. Zhuang, F. Luan, C. Zhao, and M. Cordeiro, Interaction of coumarin phytoestrogens with ERα and ERβ: A molecular dynamics simulation study, Molecules 25 (2020), pp. 1165. doi:https://doi.org/10.3390/molecules25051165.
- C. Deng, X. Chen, H. Lu, X. Yang, F. Luan, and M. Natalia Dias Soeiro Cordeiro, Prediction of the estrogen receptor binding affinity for both hERα and hERβ by QSAR approaches, Lett. Drug Des. Discov. 11 (2014), pp. 265–278. doi:https://doi.org/10.2174/15701808113109990067.
- Q. Zhao, Y. Lu, Y. Zhao, R. Li, F. Luan, and N.D. Cordeiro, Rational design of multi-target estrogen receptors ERα and ERβ by QSAR approaches, Curr. Drug Targets 18 (2017), pp. 576–591. doi:https://doi.org/10.2174/1389450117666160401125542.
- L. Miao and H. Tian, Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations, J. Drug Target 28 (2020), pp. 154–165. doi:https://doi.org/10.1080/1061186X.2019.1648477.
- S. Pathania, P.K. Singh, R.K. Narang, and R.K. Rawal, Identifying novel putative ERK1/2 inhibitors via hybrid scaffold hopping–FBDD approach, J. Biomol. Struct. Dyn. (2021), pp. 1–16. doi:https://doi.org/10.1080/07391102.2021.1889670.
- E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J.Y. Xiang, L. Wang, D. Lupyan, M.K. Dahlgren, and J.L. Knight, OPLS3: A force field providing broad coverage of drug-like small molecules and proteins, J. Chem. Theory Comput. 12 (2016), pp. 281–296. doi:https://doi.org/10.1021/acs.jctc.5b00864.
- T.D. Heightman, V. Berdini, H. Braithwaite, I.M. Buck, M. Cassidy, J. Castro, A. Courtin, J.E. Day, C. East, and L. Fazal, Fragment-based discovery of a potent, orally bioavailable inhibitor that modulates the phosphorylation and catalytic activity of ERK1/2, J. Med. Chem. 61 (2018), pp. 4978–4992. doi:https://doi.org/10.1021/acs.jmedchem.8b00421.
- T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks, Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, J. Med. Chem. 47 (2004), pp. 1750–1759. doi:https://doi.org/10.1021/jm030644s.
- R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes, J. Med. Chem. 49 (2006), pp. 6177–6196. doi:https://doi.org/10.1021/jm051256o.
- D.E. Shaw, A fast, scalable method for the parallel evaluation of distance-limited pairwise particle interactions, J. Comput. Chem. 26 (2005), pp. 1318–1328. doi:https://doi.org/10.1002/jcc.20267.
- P. Kumar Singh and O. Silakari, In silico guided development of imine-based inhibitors for resistance-deriving kinases, J. Biomol. Struct. Dyn. 37 (2019), pp. 2593–2599. doi:https://doi.org/10.1080/07391102.2018.1491893.
- S. Genheden and U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov. 10 (2015), pp. 449–461. doi:https://doi.org/10.1517/17460441.2015.1032936.
- P. Singh and O. Silakari, Molecular dynamics and pharmacophore modelling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC, SAR QSAR Environ. Res. 28 (2017), pp. 221–233. doi:https://doi.org/10.1080/1062936X.2017.1300189.
- M.P. Jacobson, D.L. Pincus, C.S. Rapp, T.J. Day, B. Honig, D.E. Shaw, and R.A. Friesner, A hierarchical approach to all-atom protein loop prediction, Proteins Struct. Funct. Bioinf. 55 (2004), pp. 351–367. doi:https://doi.org/10.1002/prot.10613.
- M.D. Parenti and G. Rastelli, Advances and applications of binding affinity prediction methods in drug discovery. Biotechnol. Adv. 30 (2012), pp. 244–250. doi:https://doi.org/10.1016/j.biotechadv.2011.08.003.
- L. Schrödinger, QikProp, Version 3.5, Schrödinger, New York, NY, 2012.
- H. Ma, S. Deacon, and K. Horiuchi, The challenge of selecting protein kinase assays for lead discovery optimization, Expert Opin. Drug Discov. 3 (2008), pp. 607–621. doi:https://doi.org/10.1517/17460441.3.6.607.
- Y. Jia, C.M. Quinn, S. Kwak, and R.V. Talanian, Current in vitro kinase assay technologies: The quest for a universal format, Curr. Drug Discov. Technol. 5 (2008), pp. 59–69. doi:https://doi.org/10.2174/157016308783769414.
- V. Kushwah, S.S. Katiyar, C.P. Dora, A.K. Agrawal, D.A. Lamprou, R.C. Gupta, and S. Jain, Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management, Acta Biomater. 73 (2018), pp. 424–436. doi:https://doi.org/10.1016/j.actbio.2018.03.057.
- V. Kushwah, A.K. Agrawal, C.P. Dora, D. Mallinson, D.A. Lamprou, R.C. Gupta, and S. Jain, Novel gemcitabine conjugated albumin nanoparticles: A potential strategy to enhance drug efficacy in pancreatic cancer treatment, Pharm. Res. 34 (2017), pp. 2295–2311. doi:https://doi.org/10.1007/s11095-017-2238-8.
- P.K. Singh, D. Chaudhari, S. Jain, and O. Silakari, Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC, Bioorg. Med. Chem. Lett. 29 (2019), pp. 1565–1571. doi:https://doi.org/10.1016/j.bmcl.2019.05.004.
- R.K. Rawal, R. Tripathi, S. Katti, C. Pannecouque, and E. De Clercq, Design and synthesis of 2-(2, 6-dibromophenyl)-3-heteroaryl-1, 3-thiazolidin-4-ones as anti-HIV agents, Eur. J. Med. Chem. 43 (2008), pp. 2800–2806. doi:https://doi.org/10.1016/j.ejmech.2007.12.015.
- R.K. Rawal, R. Tripathi, S. Katti, C. Pannecouque, and E. De Clercq, Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1, 3-thiazolidin-4-ones as anti-HIV agents, Bioorg. Med. Chem. 15 (2007), pp. 1725–1731. doi:https://doi.org/10.1016/j.bmc.2006.12.003.
- R.K. Rawal, Y.S. Prabhakar, S. Katti, and E. De Clercq, 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors, Bioorg. Med. Chem. 13 (2005), pp. 6771–6776. doi:https://doi.org/10.1016/j.bmc.2005.07.063.
- W.S. Lau, W.F. Chen, R.Y.K. Chan, D.A. Guo, and M.S. Wong, Mitogen‐activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells, Br. J. Pharmacol. 156 (2009), pp. 1136–1146. doi:https://doi.org/10.1111/j.1476-5381.2009.00123.x.